Clinical Trials Logo

Malignant Neoplasm clinical trials

View clinical trials related to Malignant Neoplasm.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 3

NCT ID: NCT01806129 Active, not recruiting - Malignant Neoplasm Clinical Trials

Reproductive Health Program in Patients With Cancer

EROS
Start date: September 2, 2016
Phase: N/A
Study type: Interventional

This clinical trial studies reproductive health program in patients with cancer. A reproductive health program may improve patients' understanding of reproductive risks and receipt of appropriate treatment to achieve their reproductive health goals.

NCT ID: NCT01721343 Active, not recruiting - Pain Clinical Trials

Collaborative Targeted Case Management in Improving Functional Status in Patients With Stage III-IV Cancer

Start date: November 7, 2012
Phase: N/A
Study type: Interventional

This randomized clinical trial studies collaborative targeted case management in improving functional status in patients with stage III-IV cancer. Collaborative targeted case management may improve functional mobility, improve quality of life, and reduce pain and health care utilization in patients with advanced cancer

NCT ID: NCT01697527 Active, not recruiting - Malignant Neoplasm Clinical Trials

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Start date: November 2, 2012
Phase: Phase 2
Study type: Interventional

This phase II trial will examine whether genetically reprogramming a patient's disease fighting white blood cells may build an immune response to kill cancer cells that express the NY-ESO-1 protein. In this study, this genetic therapy will be given during a stem cell transplant along with a vaccine therapy. The vaccine will be made using the NY-ESO-1 protein and may help to stimulate the engineered immune response to tumor cells.

NCT ID: NCT01552434 Active, not recruiting - Malignant Neoplasm Clinical Trials

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Start date: March 16, 2012
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of bevacizumab and temsirolimus alone or in combination with valproic acid or cetuximab in treating patients with a malignancy that has spread to other places in the body or other disease that is not cancerous. Immunotherapy with bevacizumab and cetuximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as valproic acid, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether bevacizumab and temsirolimus work better when given alone or with valproic acid or cetuximab in treating patients with a malignancy or other disease that is not cancerous.

NCT ID: NCT01393821 Active, not recruiting - Pain Clinical Trials

Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab

Start date: January 23, 2012
Phase: N/A
Study type: Interventional

This clinical trial studies menadione topical lotion in treating skin discomfort and psychological distress in patients with cancer receiving panitumumab, erlotinib hydrochloride, or cetuximab. Menadione topical lotion may prevent rash or other skin discomfort and help alleviate psychological distress and pain in patients receiving treatment with panitumumab, erlotinib hydrochloride, or cetuximab

NCT ID: NCT01174264 Active, not recruiting - Malignant Neoplasm Clinical Trials

Evaluation of Food Effect on Pharmacokinetics of Vismodegib

Start date: October 2009
Phase: Phase 1/Phase 2
Study type: Interventional

This randomized clinical trial studies the effect of food on the pharmacokinetics of vismodegib. Studying the effects of meals on the absorption of vismodegib may help doctors prescribe correct doses and label the drug accurately.